Glycoprotein Ilb/IIIa-receptor antagonists

Badawy, S.I., Williams, R.C., and Gilbert, D.L., Chemical stability of an ester prodrug of a glycoprotein Ilb/IIIa receptor antagonist in solid dosage forms,. Pharm. Sci., 88, 428,1999. 

Atwater BD, Roe MT, Mahaffey KW. Platelet glycoprotein Ilb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes a review and guide to patient selection. Drugs. 2005 65 313-324. 

Ferguson JJ, Zaqqa M. Platelet glycoprotein Ilb/IIIa receptor antagonists. Drugs 1999 S8 965-82. 

Rare cases of acute profound thrombocytopenia (i.e., platelet count <20,000/mm ) have been reported with the glycoprotein Ilb/IIIa receptor antagonist abciximab. ° Although the mechanism is unknown, it is thought that abciximab binding to the glyco-... 

Hetero Diels-Alder-Biocatalysis approach for the synthesis of (S)-3- 2-[(methyl-sulfonyl) oxy]ethoxy -4-(triphenylmeth-oxy)-l-butanol methanesulfo-nate successful application of an enzyme resolution process Multi-kilo resolution of XU305, a key intermediate to the platelet glycoprotein Ilb/IIIa receptor antagonist roxifiban via kinetic and dynamic enzymatic resolution... 

The standard antiplatelet regimen for patients undergoing carotid artery stenting include aspirin 325 mg a day and clopidogrel 75 mg a day for at least one week prior to the procedure. Currently, there is no role for elective use of glycoprotein Ilb-IIIa receptor antagonists. All patients should be adequately hydrated to reduce the incidence and severity of intraprocedural hypotension. Traditionally, all antihypertensive medications are withheld on the day of the procedure. This is done to avoid excessive hypotension after CAS, particularly in patients with known severe coronary artery disease or critical aortic stenosis. 

Eptifibatide is a reversible inhibitor of the glycoprotein Ilh/nia receptor, an integrin on the surface of platelets that serves as a key regulator of platelet aggregation. Glycoprotein Ilb/IIIa receptor antagonists help to prevent platelet-induced occlusion of coronary stents. The answer is (E). 

The introduction of glycoprotein Ilb/IIIa receptor antagonists in the mid-1990s was an important advance in adjunctive pharmacological therapy for mechanical reperfusion. Preliminary data were reported... 

---